X4 Pharmaceuticals, Inc (XFOR): Operating Income
-$86.88M
Year ended 2025-12-31
-$87.91M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$86.88M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$36.40M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$107.52M | n/m | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | -$87.57M | n/m | 2025-03-26, From 2022-01-01 |
| 2021-12-31 | -$85.11M | n/m | 2024-03-21, From 2021-01-01 |
| 2020-12-31 | -$59.87M | n/m | 2023-03-21, From 2020-01-01 |
| 2019-12-31 | -$51.70M | n/m | 2022-03-17, From 2019-01-01 |
| 2018-12-31 | -$29.09M | n/m | 2021-03-19, From 2018-01-01 |
| 2017-12-31 | -$22.25M | n/c | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | -$24.35M | n/a | 2019-03-11, From 2016-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | -$86.88M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | -$115.22M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | -$52.15M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | -$349.40M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$121.24M | n/m |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | -$131.84M | n/m |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | -$160.01M | n/m |
| Scilex Holding Co (SCLX) | 2025-12-31 | -$346.01M | n/m |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | -$6.28M | n/m |
Compare XFOR, CCCC, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗